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cis-Pt I2(NH3)2: a reappraisal†
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Annarosa Arcangeli,b Gianluca Bartoli,b Mirko Severi,e Alessandro Lunghi,e
Federico Totti,e Chiara Gabbiani,f Adóracion G. Quirogag and Luigi Messori*a
The investigation of cis-PtI2(NH3)2, the diiodido analogue of cisplatin (cisPtI2 hereafter), has been unjustly
overlooked so far mainly because of old claims of pharmacological inactivity. Some recent – but still frag-
mentary – ﬁndings prompted us to reconsider more systematically the chemical and biological proﬁle of
cisPtI2 in comparison with cisplatin. Its solution behaviour, interactions with DNA and cytotoxic properties
versus selected cancer cell lines were thus extensively analysed through a variety of biophysical and com-
putational methods. Notably, we found that cisPtI2 is highly cytotoxic in vitro toward a few solid tumour
cell lines and that its DNA platination pattern closely reproduces that of cisplatin; cisPtI2 is also shown to
completely overcome resistance to cisplatin in a platinum resistant cancer cell line. The diﬀerences in the
biological actions of these two Pt complexes are most likely related to slight but meaningful diﬀerences in
their solution behaviour and reactivity. Overall, a very encouraging and unexpected pharmacological
proﬁle emerges for cisPtI2 with relevant implications both in terms of mechanistic knowledge and of pro-
spective clinical application. An ab initio DFT study is also included to support the interpretation of the
solution behaviour of cisPtI2 under physiological and slightly acidic pH conditions.
Introduction
Cisplatin is a leading compound in the field of anticancer
drugs. Together with its two main parent Pt drugs, i.e. carbo-
platin and oxaliplatin, it is currently used in about half of
chemotherapeutic protocols for cancer treatment.1–3 Since the
discovery of its outstanding anticancer properties during the
60s and subsequent clinical approval by FDA, in 1978, cispla-
tin has been the subject of hundreds of studies to describe
and understand its peculiar chemical behaviour, and elucidate
the mechanisms of its biological and pharmacological
eﬀects.4–6
A quite wide consensus now exists concerning the likely
mode of action of anticancer Pt drugs that mainly relies on
direct DNA damage, impairment of fundamental DNA func-
tions and consequent triggering of apoptosis;1,2 yet, several
issues and details remain unexplored and/or unanswered, so
that other mechanistic hypotheses – even DNA unrelated –
have been advanced.7,8
The great clinical success of cisplatin has inspired
an intense search for platinum analogues with hopefully
improved biological and pharmacological properties;9–13
however, the outcomes of these research activities turned out
to be quite modest and disappointing, both in terms of identi-
fication of new clinically eﬀective Pt agents and discovery of
innovative modes of action.
Despite the huge research eﬀorts made on platinum ana-
logues over the last three decades, we were surprised on learn-
ing that only rare studies were carried out on cisPtI2, the strict iodo
analogue of cisplatin (Fig. 1). This is probably the consequence
Fig. 1 Structure of cisplatin and its diiodido analogue.
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of an initial negative assessment by Hoeschele and Cleare,14a
who reported that cisPtI2 is nearly inactive in animal models of
sarcoma 180 while warning about its extremely low aqueous
solubility and the diﬃculty in determining the toxic dose.
Accordingly, even the cytotoxicity profile of cisPtI2 against the
60 cancer cell lines panel of NCI has never been reported.
However, more recently, a few studies started reconsidering
iodido platinum complexes as possible anticancer drug candi-
dates. For instance, Kratochwil et al., described some diamino
diiodido platinum(II) complexes manifesting an appreciable
cytotoxicity in vitro.15 In the last few years, we discovered that
some mixed diamino diiodido Pt complexes exhibit appreci-
able cytotoxic properties in vitro.16–18 Moreover, for some of
these Pt complexes, in spite of their lower reactivity with DNA
as compared to cisplatin, an unconventional reactivity toward
the model protein cytochrome c was disclosed, unexpectedly
characterized by the loss of the amino ligands and retention of
the iodido ligands.16,17 Furthermore, in a paper published in
2013, we structurally described the reaction of cisPtI2 with lyso-
zyme, confirming the peculiar and diﬀerent interaction mode
toward this model protein in comparison with cisplatin.19 Yet,
no study has re-evaluated so far the biological profile of cisPtI2.
Altogether, these arguments led us to reconsider, in a more
systematic way, some key chemical and biological aspects of
cisPtI2 with respect to cisplatin.
Specifically, we have focused our attention on the following
four issues: (i) the activation process of cisPtI2 in aqueous solu-
tions both at physiological and slightly acidic pH; (ii) a compu-
tational rationalization of the spectral results; (iii) the
investigation of the direct reaction of cisPtI2 with DNA; (iv) the
cellular eﬀects of cisPtI2 in a small panel of cancer cell lines.
Some notable results have emerged from these studies that are
comprehensively analysed and discussed here in direct com-
parison with cisplatin, with relevant mechanistic and medical
implications.
Experimental
Chemistry of cis-PtI2(NH3)2
Synthesis of cis-PtI2(NH3)2 and UV-Vis analysis. cisPtI2 was
synthesized according to published procedures, using (1 : 4)
Pt : KI in order to avoid further purifications.17,20 The purity of
the product was checked by elemental analysis of C, N and H
[calculated C: 0%, H: 1.26%, N: 5.84%, experimental: C: 0%,
H: 1.12%, N: 5.71%], and as described in ref. 14b. The correct
cis geometry was assessed by comparison with its trans ana-
logue as describe in the literature.14 Solution behaviour of
cisPtI2 was assessed through spectrophotometric studies per-
formed with a Varian Cary 50 Bio UV-Vis spectrophotometer in
buﬀered solutions without the use of DMSO and in the
absence of NaCl. A solution of the complex (10−4 M) was pre-
pared in 50 mM phosphate buﬀer (with or without the pres-
ence of KI) at pH = 7.4 or in 20 mM ammonium acetate buﬀer
at pH = 4.5 and the absorbance was monitored in the wave-
length range between 200 and 800 nm for 72 h at 25° C.
Density functional theory simulations. ORCA package has
been used throughout the calculations.21 Hybrid PBE0 func-
tional22 and Aldrich TZVP Gaussian basis sets with scalar rela-
tivistic (ZORA) corrections23 were used for both geometry
optimizations and spectra simulations. Excited states have
been computed within the TDDFT approach24 and only the
first twenty transitions have been computed using 200 expan-
sion vectors in the iterative solution of the CI equations. D3
Grimme’s dispersion corrections25 have also been included.
Solvent eﬀects have been taken into account within the
COSMO model26,27 with an ε value of 80.4. Highly accurate
integration grids (Grid 5 in the ORCA notation) without
pruning of the inner angular part of the wave function and
“TightSCF” convergence criteria have been used throughout all
the calculations.
Log P determination. The octanol–water partition coeﬃ-
cients for cisplatin and cisPtI2 were determined by modifi-
cation of the reported shake flask method.28 Water (50 mL,
distilled after Milli-Q purification) and n-octanol (50 mL) were
shaken together for 72 h to allow saturation of both phases.
Solution of the complexes were prepared in the aqueous phase
(3 × 10−3 M) and an equal volume of octanol was added. Bipha-
sic solutions were mixed for ten minutes and then centrifuged
for five minutes at 6000 rpm to allow separation. Concen-
tration in both phases was determined by UV-VIS. Reported
log P is defined as log[complex]oct/[complex]wat. Final values
were reported as the mean of three determinations.
Uptake experiment: comparison between cisplatin and cis-
PtI2(NH3)2 HCT116 cell line. The determination of platinum
concentration in the cellular pellets as well as in the corres-
ponding supernatant samples was performed in triplicate by a
Varian 720-ES Inductively Coupled Plasma Atomic Emission
Spectrometer (ICP-AES) equipped with a CETAC U5000 AT+
ultrasonic nebulizer, in order to increase the method sensi-
tivity. Before the analysis, samples were weighed in PE vials
and digested in a thermo-reactor at 80 °C for 24 h with 2 mL of
aqua regia (HCl suprapure grade and HNO3 suprapure grade in
3 : 1 ratio) and 0.2 mL of H2O2 suprapure grade. After diges-
tion, the samples were diluted to about 5 mL with ultrapure
water (≤18 MΩ) and accurately weighed; 5.0 mL of each
sample were spiked with 1 ppm of Ge used as an internal
standard and analysed. Calibration standards were prepared
by gravimetric serial dilution from a commercial standard
solution of Pt at 1000 mg L−1. The wavelength used for Pt
determination was 214.424 nm whereas for Ge the line at
209.426 nm was used. The operating conditions were opti-
mized to obtain maximum signal intensity, and between each
sample, a rinse solution of HCl suprapure grade and HNO3
suprapure grade in 3 : 1 ratio was used in order to avoid any
“memory eﬀect”.
Cellular studies
Cell cultures. PANC-1, HCT116-S, HCT116-R, IGROV-1, A549
and HT29 cell lines were cultured in RPMI 1640 (Euroclone;
Milan, Italy) with 10% Fetal Bovine Serum (FBS) (Euroclone
Defined; Euroclone; Milan, Italy). HCT116 cells were kindly
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provided by Dr R. Falcioni (Regina Elena Cancer Institute,
Roma). We cultured the cell lines at 37 °C under a humidified
atmosphere in 5% CO2 in air.
Pharmacology experiments. Cells were seeded in a 96-well
flat-bottomed plate (Corning-Costar, Corning, NY, USA) at a
cell density of 1 × 104 cells per well in RPMI complete
medium. Drugs were used, after solubilisation in water,
without using DMSO, at the final concentrations indicated in
the figures and in the legends to the figures. After 24 h, viable
cells (determined by Trypan blue exclusion) were counted in
triplicate using a haemocytometer. Each experimental point
represents the mean of four samples carried out in three
separate experiments.
Trypan blue assay. Cells viability was assessed by the Trypan
blue exclusion assay. In brief, 10 µL of 0.4% trypan blue solu-
tion was added to 10 µL cell suspensions in culture medium.
The suspension was gently mixed and transferred to a
haemocytometer. Viable and dead cells were identified and
counted under a light microscope. Blue cells failing to exclude
the dyes were considered nonviable, and transparent cells were
considered viable. The percentage of viable cells was calculated
on the basis of the total number of cells (viable plus non-
viable). The IC50 value (i.e., the dose that caused apoptosis of
50% of cells) was calculated by fitting the data points (after
24 h of incubation) with a sigmoidal curve using Calcusyn
software.
Cell cycle analysis. The eﬀect of cisplatin and cisPtI2 on cell
cycle distribution was assessed by flow cytometry after staining
the cells with propidium iodide (PI). Briefly, the cells (5 × 105
cells per mL) were analyzed prior to and after treatment with
IC50s of both drugs (20.98 µM and 7.3 µM) for 24 h. The cells
were harvested, washed with PBS and resuspended in 300 μL
1× propidium iodide staining solution and incubated at 4 °C
in the dark for 20 minutes. DNA content of the cells was
measured by BD FACSCanto Flow Cytometer and the popu-
lation of each phase was determined using ModFit LT 3.0 ana-
lysis software (Verity Software House, Topsham, ME USA).
DNA binding studies
Reaction of cisPtI2 with DNA, its putative main target, was ana-
lysed in direct comparison with cisplatin through a robust
experimental approach including quantification of Pt binding
to DNA, DNA interstrand cross-linking analysis, DNA adducts
characterization by ethidium bromide fluorescence, DNA
unwinding and thermal stability analyses.
Quantitative evaluation of binding of cis-PtI2(NH3)2 and
cisplatin to mammalian DNA in a cell-free medium. Solutions
of double-helical calf thymus (CT) DNA (42% G + C, mean
molecular mass approximately 2 × 107) at a concentration of
0.032 mg mL−1 (1 × 10−4 M related to the phosphorus content)
were incubated with cisPtI2 (8 μM) or cisplatin (8 μM) at a value
of rf = 0.08 in 0.1 mM KI or KCl, respectively, at 37 °C (rf is
defined as the molar ratio of free platinum complex to nucleo-
tide phosphates at the onset of incubation with DNA). Two
diﬀerent stock solutions of cisPtI2 (0.1 mM) or cisplatin
(0.1 mM) were prepared. One contained the PtII complex incu-
bated for 7 days in unbuﬀered KI or KCl, respectively (0.01 M,
pH 6) at 37 °C in the dark, whereas the other contained PtII
complexes incubated for 7 days in double distilled water at
37 °C in the dark. Fifty microliters of the PtII complex aged in
KI/KCl (0.01 M) or in water were quickly mixed with 4950 μL of
DNA dissolved in NaClO4 (10 mM), and the reaction mixture
was maintained at 37 °C. In the experiments in which the PtII
complex aged in water was used, the final reaction mixture was
still supplemented at the onset of the reaction with KI or KCl
so that the resulting concentration of KI or KCl in the reaction
mixtures was always 0.1 mM. At various time intervals, an
aliquot of the reaction mixture was withdrawn and assayed by
diﬀerential pulse polarography (DPP) for platinum not bound
to DNA.29
Platination reactions. If not stated otherwise, CT or plasmid
DNAs were incubated with the platinum complex in 10 mM
NaClO4 at 37 °C in the dark. After 24 h, the samples were
exhaustively dialyzed against the medium required for sub-
sequent biochemical or biophysical analysis. An aliquot of
these samples was used to determine the value of rb (rb is
defined as the number of molecules of the platinum complex
bound per nucleotide residue) by flameless atomic absorption
spectrophotometry (FAAS) or by diﬀerential pulse polarography
(DPP).29
Unwinding of negatively supercoiled DNA. Unwinding of
closed circular supercoiled pSP73KB plasmid DNA (2455 bp)
was assayed by an agarose gel mobility shift assay.30 The
unwinding angle Φ, induced per platinum–DNA adduct was
calculated upon the determination of the rb value at which the
complete transformation of the supercoiled to the relaxed
form of the plasmid was attained. Samples of pSP73KB
plasmid were incubated with platinum compounds at 37 °C in
the dark for 24 h. The samples were subsequently subjected to
electrophoresis on 1% agarose gels running at 25 °C with tris-
(hydroxymethyl) aminomethane (Tris)-acetate–EDTA buﬀer.
The gels were then stained with EtBr, followed by photography
with a transilluminator.
DNA melting. The melting curves of CT DNAs were recorded
by measuring the absorbance at 260 nm. The melting
curves were recorded in a medium containing 0.1 M Na+
with 1 mM Tris-HCl/0.1 mM Na2H2EDTA, pH 7.4. The value of
the melting temperature (tm) was determined as the tempera-
ture corresponding to a maximum on the first derivative
profile of the melting curves.
Interstrand DNA cross-linking in a cell-free medium. cisPtI2
or cisplatin were incubated for 24 h with 0.5 µg of a linear
2686-bp fragment of pUC19 plasmid linearized by EcoRI. The
linear fragment was first 3′-end-labeled by means of the
Klenow fragment of DNA polymerase I in the presence of
[α-32P]dATP. The platinated samples were analyzed for DNA
interstrand crosslinks by previously published procedures.31,32
The number of interstrand cross-links was analyzed by electro-
phoresis under denaturing conditions on alkaline agarose gel
(1%). After the electrophoresis had been completed, the inten-
sities of the bands corresponding to single strands of DNA and
interstrand cross-linked duplex were quantified. The frequency
Paper Dalton Transactions
14898 | Dalton Trans., 2015, 44, 14896–14905 This journal is © The Royal Society of Chemistry 2015
View Article Online
of interstrand cross-links was calculated as ICL/Pt (%) = XL/
5372rb (the DNA fragment contained 5372 nucleotide resi-
dues), where ICL/Pt (%) is the number of interstrand cross-
links per adduct multiplied by 100, and XL is the number of
interstrand cross-links per molecule of the linearized DNA
duplex, which was calculated assuming a Poisson distribution
of the interstrand crosslinks as XL = −ln A, where A is the frac-
tion of molecules running as a band corresponding to the
non-cross-linked DNA.
Characterization of DNA adducts by EtBr fluorescence.
These measurements were performed on a Varian Cary
fluorescence spectrophotometer using a 1 cm quartz cell.
Fluorescence measurements were performed at an exci-
tation wavelength of 546 nm, and the emitted fluorescence was
analyzed at 590 nm. The fluorescence intensity was measured
at 25 °C in NaCl (0.4 M) to avoid secondary binding of EtBr to
DNA.26 The concentrations were 0.01 mg mL−1 for DNA and
0.04 mg mL−1 for EtBr, which corresponded to the saturation
of all intercalation sites of EtBr in DNA.33
Other physical methods. Absorption spectra were measured
with a Beckman 7400 DU spectrophotometer equipped with a
thermoelectrically controlled cell holder. The FAAS measure-
ments were conducted with a Varian AA240Z Zeeman atomic
absorption spectrometer equipped with a GTA 120 graphite
tube atomizer. The gels were visualized with a FUJIFILM BAS
2500 bioimaging analyzer, and the radioactivity associated
with the bands was quantified with an AIDA Image Analyzer.
DPP measurements were performed using an EG&G PARC
Electrochemical Analyzer, model 384B.
Results
Solution chemistry of cis-Pt I2(NH3)2: log P determination and
activation profile in aqueous buﬀers
We first investigated some unexplored chemical features of
cisPtI2; in particular we determined its log P value and
analysed its solution behaviour under various conditions and
the inherent metal complex activation processes.
The log P of cisPtI2 was measured according to the method
reported in the Experimental section; a value of −0.13 was
determined versus a value of −2.4 previously determined for
cisplatin and once again confirmed here. This result implies
that cisPtI2, in its intact form, is far more lipophylic than cis-
platin: this might have some appreciable impact on its cellular
uptake (see later).
Then, the solution behaviour of cisPtI2 was studied spectro-
photometrically under physiological-like or slightly acidic pH
conditions. Remarkably, freshly prepared aqueous solutions
of cisPtI2, at pH = 7.4, manifest two intense bands in the
UV-visible region, located at 290 and 350 nm, respectively that
allow the direct and continuous monitoring of the solution
behaviour of this platinum complex (Fig. 2).
Some important spectral changes are slowly detected con-
sisting of the progressive and regular decrease of the two main
bands and in the appearance of a new band, of lower intensity,
around 280 nm. The observed spectral changes are tentatively
traceable to the progressive release of the two iodido ligands
and to their replacement by water molecules according to a
moderately biphasic kinetics. This would mean that the aqua-
tion process of cisPtI2 is quite close to that of cisplatin, invol-
ving the progressive detachment of the two halide ligands
while both ammonia ligands are retained as confirmed by
some further experiments. In particular, addition of KI at
increasing concentrations completely eliminated and even
reverted the above described spectral changes (see ESI†)
strongly supporting the proposed interpretation. In any case,
the rate of the aquation process for cisPtI2 is appreciably
slower than that for cisplatin (by at least a factor 2) possibly
because of the greater strength of the Pt–I bond and/or greater
inertness related to the increased “soft” character of iodide
over chloride (more details of the hydrolysis process and
UV-Vis analysis are given in the ESI†).
To gain further insight into the activation processes of
cisPtI2, we also analysed its spectral behaviour under slightly
acidic conditions. Indeed, a mildly acidic environment is
thought to destabilise the ammonia ligands and thus favour
ammonia release over iodide release. Accordingly, cisPtI2 was
dissolved in an acetate buﬀer, at pH 4.5, and its spectral
changes were monitored over 72 hours. The resulting spectral
profile is shown in Fig. 3: it is apparent that the overall spectral
profile is profoundly diﬀerent from that recorded at physiologi-
cal pH. In particular, a new and quite intense visible band is
clearly detected around 410 nm, at 72 hours, whose assign-
ment is discussed later.
Computational studies, simulation of UV-Vis spectra
To interpret the reported spectral profiles at two distinct pH
values, we performed UV-Vis spectral simulations of 5 species:
the native cisPtI2, two products of the iodido aquation mechan-
ism i.e. [cis-PtI(H2O)(NH3)2]
+ (1) and [cis-Pt(H2O)2(NH3)2]
2+ (2)
Fig. 2 Time dependent UV-Vis analysis of complex cis-PtI2(NH3)2 ×
10−4 M in 50 mM phosphate buﬀer (pH = 7.4) followed for 72 h.
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and two products related to the ammonia aquation mechan-
ism i.e. [cis-PtI2(NH3)(H2O)] (3) and [cis-PtI2(H2O)2] (4).
The computed spectrum of cisPtI2 (cf. red line in Fig. 4a) is
in very good agreement with the experimental one reported in
Fig. 2. The calculated spectra for the mono- and di-iodido
hydrolysis species, i.e. (1) and (2), are reproduced close to the
experimental spectral evolution shown in Fig. 2, oﬀering
strong support to the iodide release mechanism.
Simulated band assignments were done through transition
density plots reported in Fig. 4b. It is possible to observe that,
for cisPtI2, band A is a LMCT transition, I,O(px,y) → Pt(dx2−y2),
while band B is a platinum d–d transition, Pt(dxy)→ Pt(dx2−y2).
Notably, band A changes from a LMCT to a platinum d–d
character passing from cisPtI2 to species (1) and (2). For (1),
both bands have a Pt(dxy) → Pt(dx2−y2) character. For (2) we
observed that the (B) band observed for the cisPtI2 undergoes a
blue shift until it turns into band (A).
Band B conserved the Pt(dxy) → Pt(dx2−y2) character
observed for (2). Such behavior is in agreement with expected
d orbital shift due to the substitution of a strong basic π donor
as an iodide with one water molecule.
To verify the correctness of the supposed iodide hydrolysis
mechanism for physiological-like pH conditions, we have
computed the UV-Vis spectra (see Fig. 5a) also for the species
involved in the concurrent amino hydrolysis mechanism, i.e.
(3) and (4). In this case, the two cisPtI2 bands undergo a sig-
nificant red shift keeping their shape and relative intensities
practically unchanged. Interestingly, the same behavior is
experimentally observed for acidic conditions (cf. Fig. 3),
where, indeed, the release of the ammonia ligands is expected.
Furthermore, since dimeric species of the type [Pt(amine)I2]2,
that are active on selected cancer cell lines, were reported to
have been synthesised under acidic conditions;34 additional
ESI MS experiments were carried out at pH = 4.5. Formation of
dimers in solution under the latter conditions is confirmed by
the presence of few weak peaks assignable to these species
(see ESI†).
The diﬀerence transitions MOs analysis performed for (3)
and (4) is shown in Fig. 5b; it is observed that the nature
of the main spectral transitions is retained for all species
involved. In this case, only the shift of valence molecular orbi-
tals has been observed due to similar orbital contributions of
ammonia and water molecules. Therefore bands (A) and (B)
can be described as I,O(px,y)→ Pt(dx2−y2) and Pt(dxy)→ Pt(dx2−y2)
transitions, respectively.
DNA binding properties of cis-PtI2(NH3)2
To determine the nature of the DNA interactions of cisPtI2,
the DNA binding properties of this complex were examined
through a variety of methods and compared with those of cis-
platin. First, we aimed at quantifying the binding of cisPtI2 to
mammalian (CT) double-helical DNA in a cell free medium.
The amount of platinum bound to DNA increased with
time and the times at which the binding reached 50% (t50%)
are summarized in Table 1.
Fig. 3 UV-Vis spectral changes of complex cis-PtI2(NH3)2 × 10
−4 M in
50 mM acetate buﬀer (pH = 4.5) followed for 72 h. Gray line t = 0 h, red
line t = 72 h.
Fig. 4 (a) Evolution of UV-Vis spectral features for the iodide hydrolysis
mechanism. (b) Evolution of the electronic transition’s nature of A and B
bands during the iodido aquation mechanism (cis-PtI2(NH3)2 top, [cis-
PtI(H2O)(NH3)2]
+ middle and [cis-Pt(H2O)2(NH3)2]
2+ bottom): for each
transition red densities correspond to arrival orbitals and blue densities
correspond to starting molecular orbitals. Platinum ions are coloured in
silver, nitrogen in blue, oxygen in red, iodide in violet and hydrogen in
white.
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Importantly, after 24 h, cisPtI2 and cisplatin aged in water
or in 10 mM KI/KCl were quantitatively bound. As expected,
the PtII complexes preincubated in water reacted with DNA sig-
nificantly more rapidly than those preincubated in KI/KCl
(10 mM), but the rate of the reaction of cisplatin was consider-
ably higher than that of cisPtI2.
The lower rate of the reaction of cisPtI2 with double-helical
DNA in comparison with that of cisplatin can be interpreted35
as the rate of the aquation of the leaving ligands in cisPtI2 is
significantly lower than that in cisplatin. Since interstrand and
intrastrand cross-links formation are believed to be respon-
sible for anticancer activity of bifunctional platinum com-
pounds, we have quantitated the interstrand cross-linking
eﬃciency of cisPtI2 in the linear pUC19 DNA (linearized with
EcoRI restriction enzyme). Results point out that interstrand
cross-linking eﬃciency of cisPtI2 (5 ± 2%) was similar to that of
cisplatin (6%) (see ESI† for further details).32
Afterwards, to gain more information on the adducts
formed in the reaction of cisPtI2 with DNA, in comparison with
those produced by cisplatin, experiments with the fluorescent
probe ethidium bromide have been carried out. Double helical
DNA was first modified by the PtII complex (cisPtI2 or cisplatin)
for 24 h. The levels of the modification corresponded to the
values of rb in the range between 0 and 0.1. Modification of
DNA by both platinum complexes resulted in a decrease of
EtBr fluorescence (Fig. 6).
The formation of adducts of cisPtI2 resulted in a progressive
decrease of EtBr fluorescence intensity, which was similar to
that of cisplatin. This result suggests that the conformational
distortion induced in DNA by the adducts of cisPtI2 is deloca-
lized and extends over the same number of base pairs around
the platination sites as in the case of the adducts of cisplatin.
Even the DNA unwinding experiment suggests the same
mode of metalation between cisplatin and its iodide analogue
(see ESI† for further experimental details). Using this
approach, we determined the DNA unwinding angles to be in
Fig. 5 (a) Evolution of UV-Vis spectral features for the ammonia hydro-
lysis mechanism. (b) Evolution of the electronic transition’s nature of A
and B bands during the ammonia aquation mechanism (cis-PtI2(NH3)2
top, [cis-PtI2(NH3)(H2O)] middle and [cis-PtI2(H2O)2] bottom): for each
transition red densities correspond to arrival orbitals and blue densities
correspond to starting molecular orbitals. Colour code as in Fig. 4.
Table 1 Binding of cis-PtI2(NH3)2 and cisplatin to calf thymus DNA
Compound t50%
a (min)
cis-PtI2(NH3)2 aged in H2O 105 ± 11
Cisplatin aged in H2O 64 ± 5
cis-PtI2(NH3)2 aged in 10 mM KI 390 ± 24
Cisplatin aged in 10 mM KCl 136 ± 19
a The time at which the binding reached 50%. Values shown in the
table are the means ± SEM of three separate experiments.
Fig. 6 Ethidium bromide ﬂuorescence. Dependences of the EtBr ﬂuor-
escence on rb for CT DNA modiﬁed by platinum complexes in 10 mM
NaClO4 at 37 °C for 24 h. Open symbols, cis-PtI2(NH3)2; closed symbols,
cisplatin.
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the range 11 ± 2° for cisPtI2, which is very similar to that found
for cisplatin (13°).30 Finally the thermal stability experiment of
DNA has been carried out.
CT DNA was modified by cisPtI2 to the value of rb =
0.03–0.09. After the modification, the salt concentration was
further adjusted to 0.1 M by the addition of NaCl, and the
samples were further supplemented by Tris-HCl (1 mM) and
EDTA (0.1 mM). Thus, the melting curves for DNA modified by
the platinum compounds were measured at a relatively high
salt concentration (Table 2). We found that the eﬀect of DNA
platination by cisPtI2 on the melting temperature of DNA (tm)
is similar to that observed for the modifications by cisplatin.
Previously, three major factors have been used to account
for the thermal stability of DNA modified by PtII complexes
capable of DNA cross-linking. The observed total change in
melting temperature of DNA is a consequence of the relative
proportion and contribution of these three factors.36
These three factors are (i) a destabilizing eﬀect of confor-
mational distortions due to the formation of cross-links
induced in DNA by platinum coordination; (ii) the stabilizing
eﬀects of DNA interstrand cross-links which prevent dis-
sociation of DNA strands; (iii) the positive charge on the PtII
centers (introduction of a positive charge into the DNA mole-
cule, e.g. by binding of positively charged ligands such as PtII
moieties of platinum compounds, results in a stabilization of
the DNA duplex by decreasing the electrostatic repulsion of
negative charges of phosphate groups located at the comp-
lementary strands).
Thus, it is reasonable to conclude that the decreases in tm
are caused by destabilizing conformational distortions and
that these destabilizing factors dominate over the interstrand
cross-links formed by both cis-platinum compounds and by
positive charges on platinum moieties.
Owing to the fact that both cisPtI2 and cisplatin carry the
same 2+ charge on platinum moiety and form approximately
identical amounts of interstrand cross-links (5 or 6%, respecti-
vely, vide supra), the values of tm yielded by the adducts of
both complexes reflect mainly the destabilizing eﬀects of
conformational distortions induced by the platinum–DNA
adducts. Hence, the results of DNA melting experiments are
consistent with the hypothesis that DNA adducts of cisPtI2
distort and destabilize double helix of DNA approximately to
the same extent as the DNA adducts of cisplatin.
From overall inspection of the obtained results it is evident
that cisPtI2 interacts with DNA through a mode of interaction
that is very similar to that well documented for cisplatin.
Apparently, the major diﬀerence consists of a somewhat slower
kinetics of platinum association to DNA while the formed
adducts are apparently the same.
Cellular actions of cis-Pt I2(NH3)2
Afterwards, the antiproliferative eﬀects of cisPtI2 were evalu-
ated in a representative panel of cancer cell lines according to
the method described in the Experimental section.
The cancer cell panel included the following lines: PANC-1
(human pancreatic cancer), IGROV-1 (human ovarian cancer),
A549 (human lung cancer), HT29 (human colon cancer),
HCT116-S and HCT116-R (human colon cancer). These cells
were exposed to increasing concentrations of the drugs in the
range 0–200 μM; after 24 hours viable cells (determined by
Trypan blue exclusion) were counted and the IC50 values deter-
mined. The measured IC50 values are reported in Table 3.
From data inspection it is evident that cisPtI2, in the four
cisplatin sensitive cell lines, produces on the whole cytotoxic
eﬀects comparable and often greater than cisplatin. Extremely
meaningful is the case of IGROV-1 where the cytotoxicity of
cisPtI2 is far higher than cisplatin (IC50 = 7.36 μM versus
25.30 μM). Moreover, very remarkably, cisPtI2 is found to com-
pletely overcome resistance to cisplatin in the cisplatin-resist-
ant HCT116-R line. These results are very relevant and
unexpected if one considers that cisPtI2 is commonly known to
be inactive.
The eﬀects of cisPtI2 on the cell cycle were also analysed in
HCT116-R cells in comparison with cisplatin; an arrest in
the G2/M phase is clearly detected in both cases as well as a
decrease of the S phase (Fig. 7).
Analytical determinations were then carried out to measure
intracellular Pt content in HCT116-S and HCT116-R cells after
exposure to equimolar concentrations of either cisplatin or
cisPtI2. More precisely, cells were exposed to a 20 µM concen-
tration of the Pt complexes for 3 h. Results expressed as Pt
content per cell in the various cases and as percentage of inter-
nalised Pt are reported in Table 4.
From the inspection of Table 4 it is evident that cisPtI2
manifests a greater ability to enter both types of cells than cis-
platin; such a diﬀerence is more evident in the Pt resistant cell
line compared to the Pt sensitive one (5 folds vs. 2 folds). This
Table 3 IC50 values (µM) of cisplatin and its iodo analogue in a panel of
cancer cell lines
Cell line Cisplatin cis-PtI2(NH3)2
PANC-1 2.48 ± 0.11 0.91 ± 0.10
IGROV-1 25.30 ± 0.40 7.36 ± 0.31
A549 5.77 ± 0.60 3.54 ± 0.49
HT29 16.39 ± 1.10 11.69 ± 1.40
HCT116-S 7.65 ± 0.63 13.42 ± 0.49
HCT116-R 21.96 ± 1.11 4.15 ± 0.23
Table 2 Δtm (°C) valuesa of CT DNA modiﬁed by cis-PtI2(NH3)2 or
cisplatinb,c
rb = 0.03 rb = 0.06 rb = 0.09
cis-PtI2(NH3)2 −1.9 ± 0.1 −5.0 ± 0.1 −7.9 ± 0.3
Cisplatin −2.1 ± 0.3 −5.2 ± 0.3 −8.3 ± 0.3
aΔtm is defined as the diﬀerence between the tm values of platinated
and unmodified DNAs. b The tm values were measured in the medium
containing NaClO4 (0.1 M), Tris-HCl (1 mM, pH 7.4) and EDTA
(0.1 mM). c Values shown in this table are the means ± SEM of three
separate experiments.
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is possibly linked to its greater lipophilic character and larger
inertness.
Furthermore, in the resistant cell line (HCT116-R), we can
pinpoint the correlation occurring between the above IC50
values and Pt uptake in the sense that a greater cytotoxicity is
associated with a greater Pt uptake – in terms of a five fold
diﬀerence – proving the capability of cisPtI2 to overcome
chemo-resistance.
Discussion and conclusions
The substantial lack of information concerning cisPtI2 despite
its striking similarity to cisplatin has inspired the present
study; notably, some crucial aspects of its chemical and bio-
logical profile have been eventually elucidated.
First, we have shown that cisPtI2 manifests a solution behav-
iour very similar to cisplatin when dissolved in an aqueous
medium, at physiological pH; indeed, as seen for cisplatin,
cisPtI2 undergoes activation through sequential slow release of
its two iodido ligands that are replaced by water molecules.
However, the process is appreciably slower than in the case of
cisplatin. These statements are clearly supported both by
experimental data (see the ESI†) and computational analysis.
The alternative hydrolysis path, where preferential release of
NH3 ligands is observed, could also be induced by changing
the pH conditions. Even in this latter case the reaction route
has been characterized by spectrophotometric analysis and
spectral simulations. The large diﬀerences observed between
the spectral patterns associated with the two possible mecha-
nisms are very consistent with our interpretation.
Then, the reactions of cisPtI2 with DNA were investigated in
detail in direct comparison with cisplatin through a robust
experimental approach involving a variety of independent bio-
physical methods. Remarkably, we found that the pattern of
DNA platination produced by cisPtI2 is highly reminiscent and
nearly superimposable to that of cisplatin though the kinetics
of the DNA metalation process is again appreciably slower.
Afterwards, the cellular eﬀects induced by cisPtI2 were
explored in a small but representative panel of solid tumor cell
lines; the panel included PANC-1 (human pancreatic cancer),
IGROV-1 (ovarian cancer), A549 (lung cancer), HT29 (colon
cancer), HCT116-S (colon cancer) and HCT116-R cells. Very
remarkably, we observed that cisPtI2, in contrast to expec-
tations and to the current opinion, is on the whole more cyto-
toxic than cisplatin in three out of four cisplatin sensitive
cancer cells; on the other hand, cisPtI2 was found to comple-
tely overcome resistance to cisplatin in the cisplatin resistant
HCT116-R cell line. This latter result implies that cisPtI2 is able
to circumvent the molecular mechanisms that reduce sensi-
tivity to cisplatin in the resistant line. On the other hand, it is
unlikely that dimeric Pt species (see the ESI†) play a major role
in the observed cytotoxicity as the latter species are detected
only at acidic pH and in very low amounts.
Analytical determinations were carried out to measure Pt
uptake in the various cases: we found that cisplatin manifested
a far lower ability to enter cells than cisPtI2. In addition, a pro-
nounced reduction of Pt uptake was detected in HCT116 resist-
ant cells in comparison with their sensitive counterparts upon
cisplatin treatment implying that this is most likely the main
mechanism of resistance. In contrast, cisPtI2 is internalised in
far greater amounts by both cell types with resistant cells even
showing a slightly greater Pt uptake.
However, the correlation between the cytotoxic potency and
the intracellular Pt content is not straightforward for both
HCT116 cellular lines. For instance, the Pt content measured
upon exposure of HCT116-S cells to cisPtI2 is more than two
times greater compared with exposure to cisplatin. Yet, cispla-
tin produces a greater cytotoxic eﬀect than cisPtI2 (by a factor
2). Pairwise, roughly comparable amounts of intracellular Pt
are found in HCT116-R and HCT116-S cells upon exposure to
cisPtI2; but cisPtI2 is far more cytotoxic in the resistant cells
compared to the sensitive ones (by a factor 3). This implies
that the nature of the cells and the nature of the Pt complex
are still important in determining the overall antiproliferative
eﬀect.
We believe that the here reported results are very meaning-
ful and innovative with respect to the current mechanistic
knowledge on cisplatin and on its analogues for the following
reasons:
1. In contrast to expectations and to early claims of inactiv-
ity cisPtI2 is found to produce cytotoxic eﬀects comparable and
often greater than those caused by cisplatin, at least in four
representative cancer cell lines;
2. cisPtI2 overcomes to a large extent resistance to cisplatin
in a cancer cell line showing acquired resistance to cisplatin,
being taken up in a far greater amount. This implies that the
recognition processes for the two Pt complexes are distinct.
3. However, the large diﬀerences measured in Pt uptake
between cisPtI2 and cisplatin do not correlate with the large
diﬀerences observed in their respective biological eﬀects. The
Fig. 7 Cell cycle analysis in HCT116 treated with cisplatin (a) or
cisPtI2 (b).
Table 4 Platinum level (per cell) measured after exposure (3 hours) of
cell lines to 20 µM of cisplatin and cisPtI2
Cell line Drug Platinum level Internalised Pt%
HCT116-S Cisplatin 2.53 × 10−8 µg 0.98
HCT116-S cis-PtI2(NH3)2 5.37 × 10
−8 µg 1.91
HCT116-R Cisplatin 1.46 × 10−8 µg 0.50
HCT116-R cis-PtI2(NH3)2 6.66 × 10
−8 µg 2.41
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nature of the Pt complex and the type of cell still play major
roles.
4. The aquation process of cisPtI2 at physiological pH repro-
duces closely that of cisplatin – though being slower – invol-
ving the progressive release of the two halide ligands; however,
at slightly acidic pH, cisPtI2 is found to release preferentially
its ammonia ligands at variance with cisplatin. These pro-
cesses are reproduced very satisfactorily through compu-
tational analysis of the respective spectral profiles. It is very
likely that these diﬀerences in reactivity between cisPtI2 and
cisplatin may lead to diﬀerent interaction modes with specific
biomolecules, in particular with proteins, thus generating dis-
tinct pharmacological profiles.
5. Remarkably, cisPtI2 produces a kind of DNA damage very
similar to cisplatin. Yet, the kinetics of Pt binding to DNA is
slower and the final level of DNA platination is appreciably
lower. As the process of DNA platination is apparently less
eﬃcient than in the case of cisplatin it is unlikely that DNA is
the only or primary target for cisPtI2, when one considers that
cisPtI2 is even more cytotoxic than cisplatin.
Altogether, the reported results delineate an extremely
favourable biological profile for cisPtI2 and strongly warrant its
further assessment in appropriate preclinical models. More-
over, at least in our opinion, these findings contain relevant
implications with respect to the postulated mode of action of
cisplatin and of its analogues. As DNA damage produced by
cisPtI2 is, on the whole, less extensive and less important than
that induced by cisplatin and the type of DNA lesion is basi-
cally the same, the view that the cytotoxic eﬀects of cisPtI2 may
arise from mechanisms other than DNA damage is supported.
However, more studies are definitely needed to further sub-
stantiate this hypothesis.
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